Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
ID | Components | Size |
A006-214 | Human LDL R | 35μg |
A007-214 | Biotinylated Human PCSK9 | 10μg |
A003-214 | Streptavidin-HRP | 10μg |
PC9-NA003 | Anti-PCSK9 Neutralizing Antibody | 40μg |
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ID | Components | Size |
A006-214 | Human LDL R | 160μg |
A007-214 | Biotinylated Human PCSK9 | 10μg |
A003-214 | Streptavidin-HRP | 10μg |
PC9-NA003 | Anti-PCSK9 Neutralizing Antibody | 200μg |
INHIBITION OF PCSK9 [BIOTINYLATED]: LDL R BINDING BY ANTI-PCSK9 NEUTRALIZING ANTIBODY
Serial dilutions of anti-PCSK9 neutralizing antibody (Catalog # PC9-NA003) (1:2 serial dilutions, from 20 μg/mL to 0.04 μg/mL or 133.33 nM to 0.26 nM) were added into Biotinylated PCSK9: LDL R binding reactions. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Evolocumab | AMG-145 | Approved | Amgen Inc, Astellas Pharma Inc | 瑞百安, Repatha | Mainland China | Atherosclerosis; Homozygous familial hypercholesterolemia | Amgen Inc | 2015-07-17 | Acute Coronary Syndrome; Hyperlipoproteinemia Type II; Diabetes Mellitus; Hyperlipidemias; Glioma; Rejection in heart transplantation; Cardiovascular Diseases; Coronary Disease; Dyslipidemias; Heterozygous familial hypercholesterolemia; Stroke; Homozygous familial hypercholesterolemia; Sepsis; Glioblastoma; Coronary Artery Disease; Hypercholesterolemia; Atherosclerosis; Diabetes Mellitus, Type 2; Myocardial Infarction; Heart Failure; HIV Infections | Details |
Alirocumab | 316P; REGN-727; SAR-236553 | Approved | Sanofi, Regeneron Pharmaceuticals Inc | 波立达, Praluent | Mainland China | Dyslipidemias; Hypercholesterolemia; Atherosclerosis | Sanofi-Aventis Groupe | 2015-07-24 | Acute Coronary Syndrome; Hyperlipidemias; Drinking Behavior; Cardiovascular Diseases; Vascular Diseases; Coronary Disease; Dyslipidemias; Heterozygous familial hypercholesterolemia; Hemorrhage; Stroke; Intracranial Arteriosclerosis; Homozygous familial hypercholesterolemia; Sepsis; Hypercholesterolemia; ST Elevation Myocardial Infarction; Diabetes Mellitus, Type 2; Atherosclerosis; Liver Diseases, Alcoholic; Plaque, Atherosclerotic; HIV Infections; Shock, Septic | Details |
Inclisiran sodium | ALN-60212; PCSK9si; ALN-PCSsc; KJX839; KJX-839 | Approved | Alnylam Pharmaceuticals Inc | Leqvio | United States | Heterozygous familial hypercholesterolemia; Atherosclerosis | Novartis Pharma Ag | 2020-12-09 | Plaque, Atherosclerotic; Homozygous familial hypercholesterolemia; Atherosclerosis; Diabetes Mellitus, Type 2; Hypercholesterolemia; Kidney Diseases; Coronary Artery Disease; Acute Coronary Syndrome; Hypolipoproteinemias; Heterozygous familial hypercholesterolemia; Coronary Disease; Dyslipidemias; Cardiovascular Diseases; Hyperlipoproteinemia Type II; Diabetes Mellitus; Hyperlipidemias | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant human anti-PCSK9 monoclonal antibody (Tasly Pharm) | B1655; B-1655 | Phase 1 Clinical | Tianjin Tasly Pharmaceutical Co Ltd | Hypercholesterolemia | Details |
PCSK9 modulator (Genekey Biotech) | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Metabolic Diseases; Inflammation | Details | |
SAL-092 | SAL092; SAL-092 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias | Details |
NN-6434 | NN-6434 | Phase 1 Clinical | Novo Nordisk A/S | Details | |
Anti-PCSK9 monoclonal antibody (Biocad) | Phase 1 Clinical | Biocad | Cardiovascular Diseases | Details | |
Lodelcizumab | LGT-209; NVP-LGT-209 | Novartis Pharma Ag | Details | ||
Recaticimab | SHR-1209 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
MEDI-4166 | MEDI-4166 | Medimmune Llc | Details | ||
BMS-844421 | BMS-PCSK9; BMS 844421; BMSPCSK9Rx; ISIS-405879 | Ionis Pharmaceuticals Inc | Details | ||
K-312 | K-312 | Kowa Co Ltd | Details | ||
DC-371739 | DC-371739 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Hypercholesterolemia; Dyslipidemias | Details |
Ralpancizumab | RN 317; PF-5335810; PF-05335810 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
CVI-LM-001 | CVI-LM-001; CVI-LM001; C-8304 | Phase 2 Clinical | Xiwei'Ai Medicine Technology (Shanghai) Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
Ebronucimab | AK-102 | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd, Yabao Us Pharmaceutical Co Ltd | Homozygous familial hypercholesterolemia; Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipidemia, Familial Combined | Details |
MIL-86 | MIL-86 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
VERVE-101 | VERVE-101 | Phase 1 Clinical | Broad Institute, Harvard University | Plaque, Atherosclerotic; Hypercholesterolemia; Heterozygous familial hypercholesterolemia | Details |
Recombinant human anti-PCSK9 monoclonal antibody (Salubris) | SAL003 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias; Hyperlipidemia, Familial Combined | Details |
RBD-7022 | RBD-7022; RBD7022 | Phase 1 Clinical | Suzhou Ruibo Biological Technology Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
AZD-8233 | AZD-8233; IONIS-AZ4-2.5-LRx; ION-449 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Hypercholesterolemia; Dyslipidemias; Kidney Failure, Chronic; Hyperlipidemias | Details |
AZD-0780 | AZD0780; AZD-0780 | Phase 1 Clinical | Astrazeneca Plc | Dyslipidemias | Details |
Lerodalcibep | LIB-003 | Phase 3 Clinical | Lib Therapeutics Llc | Atherosclerosis; Hypercholesterolemia; Stroke; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Arteriosclerosis; Hyperlipoproteinemia Type II | Details |
MK-0616 | MK-0616 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Atherosclerosis; Hypercholesterolemia; Kidney Diseases; Hyperlipoproteinemia Type II | Details |
NNC0385-0434 | NNC0385-0434 | Phase 2 Clinical | Novo Nordisk A/S | Plaque, Atherosclerotic; Diabetes Mellitus, Type 2; Hypercholesterolemia; Cardiovascular Diseases; Renal Insufficiency, Chronic; Arteriosclerosis | Details |
Ongericimab | JS-002 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Hypertriglyceridemia; Atherosclerosis; Hypercholesterolemia; Neoplasms; Dyslipidemias; Heterozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipidemia, Familial Combined | Details |
ATH-04 | ATH-04 | Phase 1 Clinical | Affiris Ag | Atherosclerosis | Details |
This web search service is supported by Google Inc.